Live Stream Preview | Integrated NK Cell Culture Protocol: A Comprehensive Analysis from Process Development to Application
Release Date:
2026-03-04 16:50
Livestream event time
March 10, 2026, 2:00 PM–3:00 PM
Integrated Solution for Immune Cells and Stem Cells
Hycells Biotechnology is a biotechnology innovation company specializing in research on primary immune cells and hepatocytes. We are committed to providing customers with comprehensive, one-stop solutions for immune cells and stem cells, leveraging scientific innovation to drive industry development and delivering expert services to empower clinical research.
Core Services and Products of Hycells Biotechnology
Compliant Cell Collection Services: The company provides immune cell and stem cell collection services that rigorously adhere to ethical standards and regulatory requirements, ensuring standardized procedures and clear sourcing to establish a compliant foundation for research and translational applications.
High-Quality Serum-Free Culture System – HiXpan Registered trademark Series: HiXpan, independently developed by Hycells Registered trademark Our serum-free culture kits are manufactured using a fully localized, end-to-end domestic production process, with all stages—from raw biological materials to finished products—carried out within China’s domestic supply chain. The kits adhere rigorously to ISO standards for raw material selection, manufacturing management, and quality control. This product series supports the cultivation of immune cells and stem cells with high purity and robust expansion efficiency. Its serum-free, animal-component–free formulation effectively eliminates batch-to-batch variability and the risk of microbial contamination, while meeting GMP manufacturing requirements and IND submission criteria, thereby helping customers significantly reduce regulatory and R&D risks.
Hycells, guided by the principles of “compliance as the cornerstone and practical effectiveness as the guiding principle,” has developed a comprehensive, benchmark integrated NK cell culture solution for clients:
Compliance First : Ensure strict compliance with industry regulations and ethical standards throughout the entire process to safeguard the project.
Policy implementation : Conduct in-depth analysis and effective implementation of key industry policies such as “818,” and proactively mitigate compliance risks.
Reduce costs and increase efficiency : By optimizing the manufacturing process, cost control and efficiency improvements can be achieved while ensuring cell quality and functionality.
Data-driven : Validate the effectiveness of the solution with rigorous experimental data, and highlight the value of the service through genuine customer feedback.
Full support : Providing end-to-end, full-process technical support spanning experimental design, process development, and scale-up to commercial production.
Online Special Topic Sharing Announcement
On Tuesday, March 10, 2026, from 2:00 PM to 3:00 PM, Xu Yuandong, Product Technology Manager at Heyou Biotechnology, will host a live webinar on “Integrated NK Cell Culture.” The session will provide an in-depth analysis of culture processes, cutting-edge solutions, and real-world industry applications, helping you unlock new possibilities in cell culture. Please scan the QR code in the image to register for this exclusive online event. We look forward to connecting with you in the digital space!
Lecturer Biography
Speaker: Xu Yuandong
Subject: NK Integrated Training Program
With nearly a decade of deep expertise in immune cell culture, the company is dedicated to the continuous optimization of culture processes for NK cells, γδ T cells, and human mesenchymal stem cells. By precisely understanding customer needs, it designs tailored, high-efficiency, stable, and GMP-compliant culture protocols that help clients overcome critical technical bottlenecks and accelerate the translation of research findings into commercial products. Backed by a strong scientific foundation and extensive industrialization experience, the company provides end-to-end solutions—covering everything from cell isolation and expansion to functional validation—for numerous leading companies in the greater health and biotechnology sectors.
Related News
818 Breakthrough Technology | Integrated Culture Protocol for γδ T Cells
The implementation of the “818 Regulations” marks the official entry of China’s cell therapy industry into a new phase of standardized development, one that prioritizes clinical efficacy as the benchmark for value, upholds rigorous compliance across the entire value chain as an inviolable baseline, and harnesses differentiated technological innovation as the core driver of progress. The Regulations explicitly restrict low-level duplication and homogeneous competition, while giving priority to the translation of technology pathways that demonstrate clear clinical value and outstanding scientific innovation, thereby establishing clear compliance boundaries and a well-defined innovation orientation for the industry’s future development.
Conference Announcement | Hycells cordially invites you to join the 3rd Boao Lecity Stem Cell Summit
From March 20 to 22, 2026, the Third Boao Lecity Stem Cell Conference, co-hosted by the China Anti-Aging Promotion Association and Hainan University, will be held in Boao Lecity, Hainan. With the theme “Cell Therapy Pioneering the Third Medical Revolution,” the conference will also make a major announcement of the latest batch of cell therapy procedures that are now permitted to be billed, thereby establishing an international high-end platform that brings together cutting-edge ideas, translates research into clinical practice, fosters industry collaboration, and jointly develops policies and standards.
A Tribute to the Woman Who Provides “Cell-Level” Protection in the Field of Life Sciences
In the world of biopharmaceuticals, cells are the fundamental units of life; at Hycells Biotechnology, women are the driving force behind global progress. From relentless pursuit in the laboratory to compassionate care on the clinical front lines, women’s sensitivity, resilience, and wisdom—like the “primary cell” technology we have meticulously cultivated—harness the most primal and essential power to propel innovation and shape the future of our field.
Hycells Biotechnology is a biotechnology innovation company specializing in research on primary immune cells and hepatocytes. We are committed to providing customers with comprehensive, one-stop solutions for immune cells and stem cells, leveraging scientific innovation to drive industry development and delivering expert services to empower clinical research.
3.0 High-Efficiency NK Serum-Free Culture Kit | Chapter 1: Cord Blood–Derived CBNK
Hycells Biotechnology’s newly launched 3.0 High-Efficiency Serum-Free NK Cell Culture Kit (Catalog No.: NK888-2L), in collaboration with the CBMC Seed Bank, provides a comprehensive, integrated cell culture solution: from thawing and recovering CBMC seed stocks or directly and efficiently expanding fresh CBMCs, to ultimately obtaining NK cells with high purity and high viability. This integrated culture system supports flexible expansion based on cell status, with a scalable culture volume of up to 10 liters, delivering outstanding culture performance and exceptional cost-effectiveness, and earning widespread trust and recognition from customers.
New Product | Hycells Announces the Launch of High-Viability Primary Hepatocyte Cells!
Within 4 hours after recovery, its cytochrome P450 enzyme activity is most similar to that in vivo, making it suitable for short-term metabolic studies.